- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04950166
A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Peritoneal Metastases in Patients Undergoing Cytoreductive Surgery
July 6, 2023 updated by: OncoNano Medicine, Inc.
A Phase 2, Single-Dose, Open-Label Study to Evaluate the Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Peritoneal Metastases, in Patients Undergoing Cytoreductive Surgery
Peritoneal carcinomatosis (PC) results from the metastasis of a primary cancer of the peritoneum (e.g., appendiceal, ovarian, uterine, colorectal, and gastric cancers) that then disseminates throughout the abdominal cavity.
Historically progression to PC was considered terminal and resulted in survival times on the scale of a few months with palliative care being the best option for patients.
More recently, cytoreductive surgery (CS) has emerged as a means to prolong and improve patient lives with a median increase in survival of up to ~5 years.
It has been reported that for every 10% increase in cytoreduction there is a 5.5% increase in median survival time.
In addition to surgical tumor debulking within the peritoneal space, it has also been shown that coupling surgical intervention with hyperthermic intraperitoneal chemotherapy (HIPEC) can have an even greater impact on patient outcomes.
Pegsitacianine, a micellar fluorescence agent, exploits the ubiquitous pH differences observed between cancerous and normal tissues.
This in turn, provides a highly sensitive and specific fluorescence response after localizing within the tumor microenvironment, thus allowing the detection of primary tumors, their margins, metastatic disease, and tumor-containing lymph nodes.
Study Overview
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Trials@OncoNanoMed.com
- Phone Number: (682) 285-1411
- Email: trials@onconanomed.com
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest Baptist Health
-
-
Ohio
-
Columbus, Ohio, United States, 43201
- The Ohio State University Wexner Medical Center / James Cancer Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19146
- Perelman School of Medicine, University of Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15212
- AHN Cancer Institute, West Penn Hospital
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Imaging and biopsy confirmed metastatic disease of peritoneal origin
Exclusion Criteria:
- Known hypersensitivity or allergy to any component of pegsitacianine
- Tumor locations the surgeon deems unfeasible to image intraoperatively
- Excessive and/or generalized metastatic disease deemed inoperative by the surgeon
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fluorescence imaging with pegsitacianine
1 mg/kg of pegsitacianine administered IV 24-72 hours prior to surgery.
|
An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinically Significant Events (CSE)
Time Frame: 1 day
|
Detection of residual disease following standard of care (SOC) resection of peritoneal metastases.
Detection of a single additional tumor-containing specimen excised as a result of pegsitacianine fluorescence will be deemed a clinically significant event (CSE)
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pegsitacianine safety
Time Frame: 30 days
|
Treatment emergent adverse events
|
30 days
|
Pegsitacianine fluorescence and imaging performance
Time Frame: 7 days
|
Sensitivity, specificity, negative and positive predictive values at the level of the individual patient specimens
|
7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 30, 2021
Primary Completion (Actual)
December 29, 2022
Study Completion (Actual)
January 20, 2023
Study Registration Dates
First Submitted
June 25, 2021
First Submitted That Met QC Criteria
June 25, 2021
First Posted (Actual)
July 6, 2021
Study Record Updates
Last Update Posted (Actual)
July 10, 2023
Last Update Submitted That Met QC Criteria
July 6, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ON-1003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peritoneal Carcinomatosis
-
Association Francaise de ChirurgieCompletedCarcinomatosis, PeritonealFrance
-
Hasselt UniversityZiekenhuis Oost-LimburgUnknownColorectal Peritoneal CarcinomatosisBelgium
-
Hospices Civils de LyonUnknownColorectal Peritoneal CarcinomatosisFrance
-
University of California, IrvineRecruitingPeritoneal Carcinomatosis | Gastrointestinal Peritoneal CarcinomatosisUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisTerminatedPatients With Gastric Peritoneal CarcinomatosisFrance
-
Hospices Civils de LyonCompletedDigestive Peritoneal CarcinomatosisFrance
-
Uppsala UniversityCompletedColorectal Peritoneal CarcinomatosisSweden
-
AIO-Studien-gGmbHNeovii BiotechCompletedGastric Adenocarcinoma With Peritoneal Carcinomatosis | Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis | Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal CarcinomatosisGermany
-
M.D. Anderson Cancer CenterCompletedPeritoneal CancerUnited States
-
Carlos ChanInstitute of Quantitative Systems Pharmacology (IQSP)RecruitingPeritoneal CarcinomatosisUnited States
Clinical Trials on pegsitacianine
-
OncoNano Medicine, Inc.Completed
-
University of Texas Southwestern Medical CenterNational Cancer Institute (NCI)RecruitingHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Unknown Primary CancerUnited States